Table 1 Select baseline demographic and clinical characteristics
| Â | PROMISE-1 | PROMISE-2 | ||||
|---|---|---|---|---|---|---|
Eptinezumab 100 mg n = 223 | Eptinezumab 300 mg n = 224 | Placebo n = 222 | Eptinezumab 100 mg n = 356 | Eptinezumab 300 mg n = 350 | Placebo n = 366 | |
Mean (SD) age, years | 40.0 (10.7) | 40.2 (11.7) | 39.9 (11.7) | 41.0 (11.7) | 41.0 (10.4) | 39.6 (11.3) |
Sex, n (%) female | 179 (80.3) | 199 (88.8) | 186 (83.8) | 307 (86.2) | 314 (89.7) | 325 (88.8) |
Mean (SD) MHDs | 10.0 (3.0) | 10.1 (3.1) | 9.9 (2.8) | 20.4 (3.1) | 20.4 (3.2) | 20.6 (3.0) |
Mean (SD) MMDs | 8.7 (2.9) | 8.6 (2.9) | 8.4 (2.7) | 16.1 (4.6) | 16.1 (4.8) | 16.2 (4.6) |
MOH diagnosis, n (%) | ‒ | ‒ | ‒ | 139 (39.0) | 147 (42.0) | 145 (39.6) |
Diagnostic category, n (%) | ||||||
 CM (≥ 15 MHDs) | 16 (7.2) | 20 (9.0) | 14 (6.3) | 356 (100) | 348 (99.4) | 366 (100) |
 HFEM (10–14 MHDs) | 102 (46.2) | 107 (48.2) | 114 (51.4) | 0 (0) | 2 (0.6) | 0 (0) |
 LFEM (4–9 MHDs) | 103 (46.6) | 95 (42.8) | 94 (42.3) | 0 (0) | 0 (0) | 0 (0) |
  ≤ 3 MHDs | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |